Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: Report of four cases

Tropical Medicine and International Health

Volumn 14, Issue 9, 2009, Pages 1064-1070

  Patel, T A ^a   Lockwood, D N ^a,b  

^a HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

HIV; Immunocompromised host; Leishmaniasis; Pentamidine; Prophylaxis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; STIBOGLUCONATE SODIUM;

ANTIBIOTICS; DISEASE CONTROL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; LEISHMANIASIS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AMASTIGOTE; BONE MARROW BIOPSY; CASE REPORT; CD4+ T LYMPHOCYTE; DRUG EFFICACY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; LEISHMANIA; MAINTENANCE THERAPY; MALE; OBSERVATIONAL STUDY; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; SKIN BIOPSY; TREATMENT DURATION; TREATMENT REFUSAL; VIRUS LOAD; VISCERAL LEISHMANIASIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIPROTOZOAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HIV-1; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIASIS, VISCERAL; LYMPHOPENIA; MALE; MIDDLE AGED; PENTAMIDINE; RECURRENCE; RETROSPECTIVE STUDIES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 69249186238     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2009.02329.x     Document Type: Review

References (51)

1. Alvar J, Canavate C, Gutierrez-Solar B, et al. (1997) Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clinical Microbiology Reviews 10, 298 319.
2. Angarano G, Maggi P, Coppola SL Cavaliere RL (1998) Itraconazole as maintenance therapy for visceral leishmaniasis in HIV-infected patients. European Journal of Clinical Microbiology and Infectious Diseases 17, 365 367.
3. Badaro R, Falcoff E, Badaro FS, et al. (1990) Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. The New England Journal of Medicine 322, 16 21.
4. Berenguer J, Cosin J, Miralles P, Lopez JC Padilla B (2000) Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 14, 2946 2948.
5. Berens RL, Marr JJ, Nelson DJ LaFon SW (1980) Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani. Biochemical Pharmacology 29, 2397 2398.
6. Borrelli P, Imperato A, Murdaca G Scudeletti M (2000) Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV. Annali Italiani di Medicina Interna 15, 169 171. (Pubitemid 30435189)
7. Bourgeois N, Lachaud L, Reynes J, et al. (2008) Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis. Journal of Acquired Immune Deficiency Syndromes 48, 13 19.
8. Bryceson A (2001) A policy for leishmaniasis with respect to the prevention and control of drug resistance. Tropical Medicine and International Health 6, 928 934.
9. Calza L, D'Antuono A, Marinacci G, et al. (2004) Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS. Journal of the American Academy of Dermatology 50, 461 465.
10. Calza L, Marinacci G, Manfredi R, et al. (2001) Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report. Journal of Chemotherapy 13, 653 657.
11. Carvalho EM, Badaro R, Reed SG, Jones TC Johnson WD Jr. (1985) Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. The Journal of Clinical Investigation 76, 2066 2069.
12. Casado JL, Lopez-Velez R, Pintado V, et al. (2001) Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. European Journal of Clinical Microbiology and Infectious Diseases 20, 202 205.
13. den Boer M Davidson RN (2006) Treatment options for visceral leishmaniasis. Expert Review of Anti-infective Therapy 4, 187 197.
14. de Rossell RA, de Duran RJ, Rossell O Rodriguez AM (1992) Is leishmaniasis ever cured? Transactions of the Royal Society of Tropical Medicine and Hygiene 86, 251 253.
15. Desjeux P Alvar J (2003) Leishmania\HIV co-infections: epidemiology in Europe. Annals of Tropical Medicine and Parasitology 97 (Suppl. 1 3 15.
16. Faraut-Gambarelli F, Piarroux R, Deniau M, et al. (1997) In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 41, 827 830.
17. Gradoni L, Scalone A, Gramiccia M Troiani M (1996) Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. AIDS 10, 785 791.
18. ter Horst R, Collin SM, Ritmeijer K, Bogale A Davidson RN (2008) Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clinical Infectious Diseases 46, 1702 1709.
19. Lafeuillade A, Chaffanjon P, Delbeke E Quilichini R (1992) Maintenance itraconazole for visceral leishmaniasis in HIV infection. The American Journal of Medicine 92, 449.
20. Laguna F, Adrados M, Alvar J, et al. (1997) Visceral leishmaniasis in patients infected with the human immunodeficiency virus. European Journal of Clinical Microbiology and Infectious Diseases 16, 898 903.
21. Laguna F, Lopez-Velez R, Pulido F, et al. (1999) Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 13, 1063 1069.
22. Laguna-del-Estal P Moya-Mir MS (1997) Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. The American Journal of Medicine 102, 222.
23. Lazanas MC, Tsekes GA, Papandreou S, et al. (1993) Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 7, 1018 1019.
24. Lopez DM, Gil AA, Lavilla UP, et al. (1993) Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases. The Journal of Antimicrobial Chemotherapy 32, 657 659.
25. Lopez-Velez R (2003) The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Annals of Tropical Medicine and Parasitology 97 (Suppl. 1 143 147.
26. Lopez-Velez R, Perez-Molina JA, Guerrero A, et al. (1998) Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. The American Journal of Tropical Medicine and Hygiene 58, 436 443.
27. Lopez-Velez R, Videla S, Marquez M, et al. (2004) Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. The Journal of Antimicrobial Chemotherapy 53, 540 543.
28. Lustig V, Kager PA Meenhorst PL (1995) Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine. The Netherlands Journal of Medicine 47, 66 69.
29. Mastroianni CM, d'Ettorre G, Forcina G, et al. (2000) Long-term remission of human immunodeficiency virus-associated visceral leishmaniasis after initiation of potent combination antiretroviral treatment: report of two cases. The Journal of Infection 40, 94 96.
30. Matheron S, Cabie A, Parquin F, et al. (1992) Visceral leishmaniasis and HIV infection: unusual presentation with pleuropulmonary involvement, and effect of secondary prophylaxis. AIDS 6, 238 240.
31. McBride M, Linney M, Claydon EJ Weber J (1994) Visceral leishmaniasis following treatment with liposomal amphotericin B. Clinical Infectious Diseases 19, 362.
32. Medrano FJ, Hernandez-Quero J, Jimenez E, et al. (1992) Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain? AIDS 6, 1499 1503.
33. Mira JA, Corzo JE, Rivero A, et al. (2004) Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. The American Journal of Tropical Medicine and Hygiene 70, 298 301.
34. Montalban C, Calleja JL, Erice A, et al. (1990) Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. The Journal of Infection 21, 261 270.
35. Montana M, Chochoi N, Monges P, et al. (2004) Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV-infected patients: report of five clinical cases. Pathologie-biologie 52, 66 75.
36. Nigro L, Cacopardo B, Preiser W, et al. (1999) In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from subjects coinfected with human immunodeficiency virus and Leishmania infantum. The American Journal of Tropical Medicine and Hygiene 60, 142 145.
37. Orlando G, Del Sorbo F, Corbellino M, Schiavini M Cargnel A (1998) Secondary prophylaxis for Leishmania infection in an HIV-positive patient. AIDS 12, 2086 2087.
38. Pasquau F, Ena J, Sanchez R, et al. (2005) Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region. The European Journal of Clinical Microbiology and Infectious Diseases 24, 411 418.
39. Perez-Molina JA, Lopez-Velez R, Montilla P Guerrero A (1996) Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients. AIDS 10, 237 238.
40. Pineda JA, Gallardo JA, Macias J, et al. (1998) Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain. Journal of Clinical Microbiology 36, 2419 2422.
41. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S Bouza E (2001) Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80, 54 73.
42. Raffi F, Merrien D, Le Pape P Reliquet V (1995) Use of an Itraconazole\allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS. Clinical Infectious Diseases 21, 1338 1339.
43. Ribera E, Ocana I, de Otero J, et al. (1996) Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. The American Journal of Medicine 100, 496 501.
44. Rosenthal E, Marty P, Le Fichoux Y Cassuto JP (2000) Clinical manifestations of visceral leishmaniasis associated with HIV infection: a retrospective study of 91 French cases. Annals of Tropical Medicine and Parasitology 94, 37 42.
45. Rosenthal E, Marty P, Poizot-Martin I, et al. (1995) Visceral leishmaniasis and HIV-1 co-infection in southern France. Transactions of the Royal Society of Tropical Medicine and Hygiene 89, 159 162.
46. Squires KE, Rosenkaimer F, Sherwood JA, et al. (1993) Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. The American Journal of Tropical Medicine and Hygiene 48, 666 669. (Pubitemid 23187196)
47. Sundar S Chatterjee M (2006) Visceral leishmaniasis - current therapeutic modalities. The Indian Journal of Medical Research 123, 345 352.
48. Sundar S, Rosenkaimer F, Lesser ML Murray HW (1995) Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. The Journal of Infectious Diseases 171, 992 996.
49. Torrus D, Boix V, Massa B, Portilla J Perez-Mateo M (1996) Fluconazole plus allopurinol in treatment of visceral leishmaniasis. The Journal of Antimicrobial Chemotherapy 37, 1042 1043.
50. Tortajada C, Perez-Cuevas B, Moreno A, et al. (2002) Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 30, 364 366.
51. World Health Organization (1997) Leishmania\HIV co-infection. Epidemiological analysis of 692 retrospective cases. Weekly Epidemiological Record 72, 49 54.